Regulation of the mevalonate pathway
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
The mevalonate pathway produces isoprenoids that are vital for diverse cellular functions, ranging from cholesterol synthesis to growth control. Several mechanisms for feedback regulation of low-density-lipoprotein receptors and of two enzymes involved in mevalonate biosynthesis ensure the production of sufficient mevalonate for several end-products. Manipulation of this regulatory system could be useful in treating certain forms of cancer as well as heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The conversion of acetyl-coenzyme A (CoA) to farnesyl diphosphate (FPP) is commonly referred to as the isoprenoid pathway, in which P-hydroxy-P-methylglutaryl(HMG)-CoA reductase is the major site of regulation [5].”
In the citing paper
“Since HMGCR encodes the rate-limiting enzyme of the cholesterol biosynthesis pathway and is tightly regulated at the level of gene transcription by sterol response element binding factor 2 (SREBF2) in response to changes in intracellular sterol content10, we identified genes whose statin-induced expression level changes were most highly correlated with statin-induced changes in HMGCR.”
From Transmembrane Protein 55B Is a Novel Regulator of Cellular Cholesterol Metabolism (2014) · cites this paper as [10]
In the citing paper
“The expression of liver LDL receptor (LDLR) regulates human plasma LDL-cholesterol (LDL-C) homeostasis”
From A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression (2014) · cites this paper as [3]
In the citing paper
“The liver is the organ responsible for removing >70% to 80% of LDL-c from circulation via LDL receptor (LDLR)–mediated endocytosis.”
In the citing paper
“Therefore, the amount of LDLR expressed on the surface of hepatocytes is a major determinant of LDL-c circulating levels.”
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Self-citationThe Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
Brown, M. S., & Goldstein, J. L. (1980) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42221-7 · Cited by 1,198
Self-citationPromoter-specific activation of RNA polymerase II transcription by Sp1
Kadonaga, J. T., Jones, K. A., & Tjian, R. (1986) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(86)90226-4 · Cited by 1,012
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Regulation of HMG-CoA Reductase
RODWELL, V. W., NORDSTROM, J. L., & MITSCHELEN, J. J. (1976) · Advances in Lipid Research · doi:10.1016/b978-0-12-024914-5.50008-5 · Cited by 746
Santoro, C., Mermod, N., Andrews, P. C., & Tjian, R. (1988) · Nature · doi:10.1038/334218a0 · Cited by 715
Segev, N., Mulholland, J., & Botstein, D. (1988) · Cell · doi:10.1016/0092-8674(88)90433-3 · Cited by 689
A family of receptors coupled to guanine nucleotide regulatory proteins
Dohlman, H. G., Caron, M. G., & Lefkowitz, R. J. (1987) · Biochemistry · doi:10.1021/bi00384a001 · Cited by 631
Research works printed but not linked: 3
- Smith, J. R., Osborne, T. F., Goldstein, J. L. & Brown, M. S. J. biol. Chem. (in the press).
- Kamiya, Y., Sakurai, A., Tamura, S. & Takahashi, N. Agric. Biol. Chem. 43, 1049–1053 (1979).
- Gibbs, J. B. & Marshall, M. S. Micro. Rev. 53, 171–185 (1989). · doi:10.1128/mr.53.2.171-185.1989 · Paper page
Cited by
Items 301–400 of 1,062
Identification of Natural RORγ Ligands that Regulate the Development of Lymphoid Cells
Santori, F. R., Huang, P., van de Pavert, S. A., Douglass, E. F., Leaver, D. J., Haubrich, B. A., Keber, R., Lorbek, G., Konijn, T., Rosales, B. N., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.004 · Cited by 235
“This suggested that Sc4mol / cells could obtain CBIs and cholesterol for cell growth via the endocytosis of exogenous LDL (Goldstein and Brown, 1990).”
BackgroundWeng, C.-H., Chen, L.-Y., Lin, Y.-C., Shih, J.-Y., Lin, Y.-C., Tseng, R.-Y., Chiu, A.-C., Yeh, Y.-H., Liu, C., Lin, Y.-T., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0454-2 · Cited by 233
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
“Statins are usually used as drugs that inhibit the mevalonate pathway to treat hypercholesterolemia [95].”
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Bühring, H.-J., Streble, A., & Valent, P. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000077351 · Cited by 231
“Statins are potent inhibitors of hydroxymethylglutaryl coenzyme A reductase, a critical enzyme in the mevalonic acid pathway [”
BackgroundOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230
“As a negative regulator of the mevalonate pathway, lovastatin can impact the production of multiple compounds involved in intracellular signaling, including ubiquinone, dolichol, and isoprenoids (Goldstein and Brown, 1990).”
Schaller, H., Grausem, B., Benveniste, P., Chye, M. L., Tan, C. T., Song, Y. H., & Chua, N. H. (1995) · Plant Physiology · doi:10.1104/pp.109.3.761 · Cited by 230
Rodríguez-Concepción, M., Forés, O., Martínez-García, J. F., González, V., Phillips, M. A., Ferrer, A., & Boronat, A. (2004) · The Plant Cell · doi:10.1105/tpc.016204 · Cited by 231
“Although the MEP pathway was elucidated only recently (reviewed by Rodríguez-Concepción and Boronat, 2002), the MVA pathway has been studied extensively in animals and yeast since the 1950s (reviewed by Goldstein and Brown, 1990).”
MethodMaeda, T., Kawane, T., & Horiuchi, N. (2003) · Endocrinology · doi:10.1210/en.2002-220682 · Cited by 230
Hampton, R. Y., & Rine, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.2.299 · Cited by 232
“Coupling the degradation of Hmg2p to the mevalonate pathway by attachment of a mevalonate pathway product to a protein involved in the degradation process would be an appealing mechanism for regulating degradation (Goldstein and Brown, 1990; Edwards et al., 1992).”
BackgroundVallett, S. M., Sanchez, H. B., Rosenfeld, J. M., & Osborne, T. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12247 · Cited by 231
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
“HMGCR acts as the rate-limiting enzyme of the mevalonate pathway, which produces cholesterol, steroid-based hormones, and non-sterol isoprenoids [23, 35].”
BackgroundWan, C., Wong, C. N., Pin, W., Wong, M. H., Kwok, C., Chan, R. Y., Yu, P. H., & Chan, S. (2013) · Phytotherapy Research · doi:10.1002/ptr.4751 · Cited by 227
Methods for Obtaining and Determination of Squalene from Natural Sources
Popa, O., Băbeanu, N. E., Popa, I., Niță, S., & Dinu-Pârvu, C. E. (2015) · BioMed Research International · doi:10.1155/2015/367202 · Cited by 222
“FPP can be further converted to squalene and sterols or involved in the synthesis of isoprenylated cellular metabolites [89].”
BackgroundVascular nitric oxide: formation and function
Loscalzo, J., & Jin (2010) · Journal of Blood Medicine · doi:10.2147/jbm.s7000 · Cited by 221
“inhibiting the reduction of HMG-CoA to mevalonate, the rate-limiting step of liver cholesterol biosynthesis.(168) Statins”
Ericsson, J., Jackson, S. M., Kim, J. B., Spiegelman, B. M., & Edwards, P. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.7298 · Cited by 230
Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase.
Schaber, M. D., O'Hara, M. B., Garsky, V. M., Mosser, S. C., Bergstrom, J. D., Moores, S. L., Marshall, M. S., Friedman, P. A., Dixon, R. A., & Gibbs, J. B. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77164-0 · Cited by 227
Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
Thurnher, M., Nussbaumer, O., & Gruenbacher, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0489 · Cited by 224
“Mevalonate synthesis and metabolism In the first committed step of the mevalonate pathway (1), which is inhibited by statins (2, 3), hydroxymethyl-”
BackgroundPruefer, D., Scalia, R., & Lefer, A. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.12.2894 · Cited by 227
“9 Rats were randomly divided into 1 of several groups: ( 1 ) Krebs-Henseleit‐superfused mesenteries, (2) mesenteries superfused with 50 mmol/L N”
MethodSoma, M. R., Donetti, E., Parolini, C., Mazzini, G., Ferrari, C., Fumagalli, R., & Paoletti, R. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.4.571 · Cited by 225
The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases
Cheuka, P., Mayoka, G., Mutai, P., & Chibale, K. (2016) · Molecules · doi:10.3390/molecules22010058 · Cited by 222
“Mevinolin, on prolonged exposure, displayed activity on both adult and juvenile worms [249,250].”
BackgroundThe Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis
Vourakis, M., Mayer, G., & Rousseau, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158074 · Cited by 217
“Only about one-quarter of the pooled body cholesterol is obtained from the diet mainly from animal and dairy food products, with the remaining ~75% being synthesized endogenously in the liver via the mevalonate pathway [25,26].”
BackgroundChoi, D., Ward, B. L., & Bostock, R. M. (1992) · The Plant Cell · doi:10.1105/tpc.4.10.1333 · Cited by 220
Jiang, X. C., Agellon, L. B., Walsh, A., Breslow, J. L., & Tall, A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115993 · Cited by 223
Park, H.-J., Zhang, Y., Georgescu, S. P., Johnson, K. L., Kong, D., & Galper, J. B. (2006) · Stem Cell Reviews · doi:10.1007/s12015-006-0015-x · Cited by 220
Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation
Tang, J., Lobatto, M. E., Hassing, L., van der Staay, S., van Rijs, S. M., Calcagno, C., Braza, M. S., Baxter, S., Fay, F., Sanchez-Gaytan, B. L., et al. (2015) · Science Advances · doi:10.1126/sciadv.1400223 · Cited by 226
“This pathway produces isoprenoids, a class of molecules used not only for cholesterol synthesis (32) but also 100 m S-HDL Placebo”
BackgroundVandermeer, M. L., Thomas, A. R., Kamimoto, L., Reingold, A., Gershman, K., Meek, J., Farley, M. M., Ryan, P., Lynfield, R., Baumbach, J., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jir695 · Cited by 224
“As inhibitors of 3-hydroxy3-methylglutaryl coenzyme A reductase, statins inhibit the synthesis of products of the mevalonate pathway, such as isoprenoids and geranyl-geranyl pyrophosphate [1, 3, 4].”
BackgroundCholesterol in signal transduction
Incardona, J. P., & Eaton, S. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00076-9 · Cited by 226
Mathur, J., Molnár, G., Fujioka, S., Takatsuto, S., Sakurai, A., Yokota, T., Adam, G., Voigt, B., Nagy, F., Maas, C., et al. (1998) · The Plant Journal · doi:10.1046/j.1365-313x.1998.00158.x · Cited by 225
Direct vascular effects of HMG-CoA reductase inhibitors
Bellosta, S., Bernini, F., Ferri, N., Quarato, P., Canavesi, M., Arnaboldi, L., Fumagalli, R., Paoletti, R., & Corsini, A. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00319-5 · Cited by 223
“However, mevalonate is not only a precursor of cholesterol, but also of a number of non-steroidal isoprenoid compounds essential for normal cellular activity, such as dolichols, heme A, ubiquinone and isopentenyladenosine, so that the inhibition of HMG-CoA reductase might have potential pleiotropic effects [15–18].”
BackgroundRecent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 221
“FXRs were found to be activated by the farnesol derivative, farnesyl pyrophosphate, which is a metabolic intermediate and the last precursor common to all branches of the mevalonic pathway, which leads to the biosynthesis of cholesterol, bile acids (BAs), sterol compounds, porphyrin, dolichol, ubiquinone, carotenoids,…”
BackgroundEvolving questions and paradigm shifts in endoplasmic‐reticulum‐associated degradation (ERAD)
McCracken, A. A., & Brodsky, J. L. (2003) · BioEssays · doi:10.1002/bies.10320 · Cited by 221
Production of Lycopene in the Non-Carotenoid-Producing Yeast Yarrowia lipolytica
Matthäus, F., Ketelhot, M., Gatter, M., & Barth, G. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.03167-13 · Cited by 220
“Here the ratelimiting step is represented by the 3-hydroxy-3-methyl-glutaryl (HMG)– coenzyme A (CoA) reductase (1, 2).”
BackgroundPai, J.-T., Guryev, O., Brown, M. S., & Goldstein, J. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.26138 · Cited by 221
Self-citationXia, Z., Tan, M., Wei-Lynn Wong, W., Dimitroulakos, J., Minden, M., & Penn, L. (2001) · Leukemia · doi:10.1038/sj.leu.2402196 · Cited by 218
Chen, Y., Tang, Y., Guo, C., Wang, J., Boral, D., & Nie, D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.030 · Cited by 219
Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H., Freedman, M. H., Minden, M. D., & Penn, L. Z. (1999) · Blood · doi:10.1182/blood.v93.4.1308 · Cited by 219
Regulation of HMG-CoA reductase activity in plants.
Stermer, B. A., Bianchini, G. M., & Korth, K. L. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39958-2 · Cited by 216
Regulation of cholesterol homeostasis
Goedeke, L., & Fernández-Hernando, C. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0857-5 · Cited by 213
“for the biosynthesis of molecules used in processes as diverse as terpenoid synthesis, protein prenylation, cell membrane maintenance, hormones, protein anchoring, and N-glycosylation [11].”
BackgroundInfluentialGallagher, C. M., Garri, C., Cain, E. L., Ang, K. K.-H., Wilson, C. G., Chen, S., Hearn, B. R., Jaishankar, P., Aranda-Diaz, A., Arkin, M. R., et al. (2016) · eLife · doi:10.7554/elife.11878 · Cited by 214
“…S5394), 50 mM compactin (aka mevastatin, a HMG-CoA reductase inhibitor, Santa Cruz Biotechnology sc-200853), 50 mM mevalonolactone to facilitate non-sterol isoprenoids (Sigma 68519) (Goldstein and Brown, 1990), 2 mM L-glutamine (Sigma G2150), 100 U penicillin 100 mg /mL streptomycin (Sigma P0781).”
BackgroundIn vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits.
Anant, J. S., Ong, O. C., Xie, H. Y., Clarke, S., O'Brien, P. J., & Fung, B. K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48336-6 · Cited by 218
Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., Inoue, M., & Nakamura, H. (2002) · Gastroenterology · doi:10.1053/gast.2002.31093 · Cited by 217
Biochemistry of protein prenylation.
Casey, P. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41331-8 · Cited by 218
Corsini, A., Mazzotti, M., Raiteri, M., Soma, M. R., Gabbiani, G., Fumagalli, R., & Paoletti, R. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90107-6 · Cited by 217
NPC1L1 and cholesterol transport
Betters, J. L., & Yu, L. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.03.030 · Cited by 215
“While much is known about cholesterol biosynthesis and its regulation [1,2], the mechanisms”
BackgroundDunn, S. E., Youssef, S., Goldstein, M. J., Prod'homme, T., Weber, M. S., Zamvil, S. S., & Steinman, L. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051129 · Cited by 211
“AT inhibits T cell growth and Th1 differentiation by preventing protein isoprenylation Farnesyl-PP serves as a metabolic precursor to a variety of isoprenoid derivatives such as decaprenyl-PP (isoprenoid moiety of ubiquinone), 2-cis-geranylgeranyl-PP (important for N-glycoprotein synthesis), and all-trans geranylgeran…”
BackgroundWang, W., Wu, X., Liu, Z., Zheng, H., & Cheng, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084921 · Cited by 208
“In the early step, farnesyl pyrophosphate (FPP) is produced by the classical mevalonate pathway, which is common to vertebrates and invertebrates [78].”
BackgroundFerreira, T. M., Coreta-Gomes, F., Ollila, O. H. S., Moreno, M. J., Vaz, W. L. C., & Topgaard, D. (2013) · Phys. Chem. Chem. Phys. · doi:10.1039/c2cp42738a · Cited by 210
Control of the innate immune response by the mevalonate pathway
Akula, M. K., Shi, M., Jiang, Z., Foster, C. E., Miao, D., Li, A. S., Zhang, X., Gavin, R. M., Forde, S. D., Germain, G., et al. (2016) · Nature Immunology · doi:10.1038/ni.3487 · Cited by 214
KAJIWARA, S., FRASER, P. D., KONDO, K., & MISAWA, N. (1997) · Biochemical Journal · doi:10.1042/bj3240421 · Cited by 211
Sato, B. K., Schulz, D., Do, P. H., & Hampton, R. Y. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.03.010 · Cited by 212
“In this way, ERAD is employed as part of the feedback regulation of sterols, and a similar mechanism operates in mammals (Goldstein and Brown, 1990; Hampton, 2002b; Hampton and Garza, 2009).”
BackgroundUncoupling Nuclear Receptor LXR and Cholesterol Metabolism in Cancer
Bovenga, F., Sabbà, C., & Moschetta, A. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.002 · Cited by 207
“GPP and FPP cause isoprenylation of the intracellular G proteins Ras and Rho, which in turn regulate the signal transduction of several membrane receptors crucial for the transcription of genes involved in cell proliferation, differentiation, and apoptosis (Goldstein and Brown, 1990).”
BackgroundRole of EGFR in the Nervous System
Romano, R., & Bucci, C. (2020) · Cells · doi:10.3390/cells9081887 · Cited by 202
THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1
Katznelson, S., Wilkinson, A. H., Kobashigawa, J. A., Wang, X.-M., Chia, D., Ozawa, M., Zhong, H.-P., Hirata, M., Cohen, A. H., Terasaki, P. I., et al. (1996) · Transplantation · doi:10.1097/00007890-199605270-00010 · Cited by 209
Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression
Searles, C. D. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00457.2005 · Cited by 210
“By inhibiting HMG CoA reductase, statins prevent the synthesis of isoprenoid intermediates in the cholesterol biosynthetic pathway (41).”
BackgroundInhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine
Warner, G. J., Berry, M. J., Moustafa, M. E., Carlson, B. A., Hatfield, D. L., & Faust, J. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001280200 · Cited by 207
Chou, J.-L., Huang, R.-L., Shay, J., Chen, L.-Y., Lin, S.-J., Yan, P. S., Chao, W.-T., Lai, Y.-H., Lai, Y.-L., Chao, T.-K., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-014-0036-2 · Cited by 206
“Furthermore, inhibition of HMG-CoA reductase by statins can also lead to a decreased level of mevalonate, which is important for the synthesis of isoprenoids including geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP) [24,31].”
BackgroundLi, H. Y., Appelbaum, F. R., Willman, C. L., Zager, R. A., & Banker, D. E. (2003) · Blood · doi:10.1182/blood-2002-07-2283 · Cited by 206
“To test this prediction, we evaluated the potential toxicity of several cholesterol-modulating agents: (1) mevastatin, which inhibits HMGCoA reductase29; (2) cholesterol oxidase (CO), which oxidizes free cholesterol30; and (3) cholesterol esterase (CE), which cleaves cholesterol esters.”
BackgroundForesti, O., Ruggiano, A., Hannibal-Bach, H. K., Ejsing, C. S., & Carvalho, P. (2013) · eLife · doi:10.7554/elife.00953 · Cited by 205
Yu, L., Bharadwaj, S., Brown, J. M., Ma, Y., Du, W., Davis, M. A., Michaely, P., Liu, P., Willingham, M. C., & Rudel, L. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511123200 · Cited by 209
Kondo, A., Yamamoto, S., Nakaki, R., Shimamura, T., Hamakubo, T., Sakai, J., Kodama, T., Yoshida, T., Aburatani, H., & Osawa, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.006 · Cited by 206
Regulation of bile acid synthesis
Vlahcevic, R. Z., Heuman, D. M., & Hylemon, P. B. (1991) · Hepatology · doi:10.1002/hep.1840130331 · Cited by 201
Keane, W. F. (1994) · Kidney International · doi:10.1038/ki.1994.349 · Cited by 209
Regulation of cholesterol homeostasis
van der Wulp, M. Y. M., Verkade, H. J., & Groen, A. K. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.007 · Cited by 205
Wine Flavonoids Protect against LDL Oxidation and Atherosclerosis
AVIRAM, M., & FUHRMAN, B. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02913.x · Cited by 206
Abd El-Hack, M. E., El-Saadony, M. T., Saad, A. M., Salem, H. M., Ashry, N. M., Abo Ghanima, M. M., Shukry, M., Swelum, A. A., Taha, A. E., El-Tahan, A. M., et al. (2022) · Poultry Science · doi:10.1016/j.psj.2021.101584 · Cited by 192
Zhu, F., Zhong, X., Hu, M., Lu, L., Deng, Z., & Liu, T. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25198 · Cited by 203
Suzuki, M., Kamide, Y., Nagata, N., Seki, H., Ohyama, K., Kato, H., Masuda, K., Sato, S., Kato, T., Tabata, S., et al. (2004) · The Plant Journal · doi:10.1111/j.1365-313x.2004.02003.x · Cited by 204
Li, W., Li, F., Zhang, X., Lin, H.-K., & Xu, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 198
“Mevalonate (MVA) is a common building block of many cellular compounds, including the membrane structure and isoprenoid/cholesterol biosynthetic precursor cholesterol,(333) the N-linked glycoproteins carrier phosphorylated dolichol,(334) the electron transfer lipid in the mitochondrial respiratory chain ubiquinone (UQ…”
BackgroundLees, N. D., Skaggs, B., Kirsch, D. R., & Bard, M. (1995) · Lipids · doi:10.1007/bf02537824 · Cited by 202
Borawski, J., Troke, P., Puyang, X., Gibaja, V., Zhao, S., Mickanin, C., Leighton-Davies, J., Wilson, C. J., Myer, V., CornellaTaracido, I., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02418-08 · Cited by 202
“Although MVD is not predicted to be a rate-limiting enzyme in cholesterol production, its inhibition would likely lead to an accumulation of phosphorylated intermediates (such as mevalonic acid pyrophosphate), which may regulate the phosphorylation state of lipid biogenesis enzymes (19).”
BackgroundLevine, T. P., & Munro, S. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.6.1633 · Cited by 205
“Indeed, oxysterols such as 25- hydroxycholesterol are up to a 1000 times more potent than cholesterol itself as down-regulators of cholesterol synthesis (Kandutsch et al., 1978; Goldstein and Brown, 1990).”
BackgroundCinnamic acid: A natural product with potential use in cancer intervention
Liu, L., Hudgins, W. R., Shack, S., Yin, M. Q., & Samid, D. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620319 · Cited by 201
Lipoproteins, cholesterol homeostasis and cardiac health
Daniels, T. F., Killinger, K. M., Michal, J. J., Wright Jr., R. W., & Jiang, Z. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.474 · Cited by 204
“The rate limiting reaction of the cholesterol biosynthesis pathway is production of mevalonate by HMG-CoA reductase (135).”
BackgroundBlanco-Colio, L. M., Villa, A., Ortego, M., Hernández-Presa, M. A., Pascual, A., Plaza, J. J., & Egido, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00613-x · Cited by 200
“HMG-CoA reductase inhibition results in the reduction of the cellular content of a variety of mevalonate metabolites [30,31].”
BackgroundCholesterol biosynthesis and metabolism
Russell, D. W. (1992) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00054556 · Cited by 200
“Alternatively, enzymes that isoprenylate proteins may serve as more focused therapeutic targets [ 13 ].”
BackgroundMethodInfluentialStatins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
von Haehling, S., & Anker, S. D. (2005) · Heart · doi:10.1136/hrt.2004.042515 · Cited by 200
Giroux, L. M., Davignon, J., & Naruszewicz, M. (1993) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(93)90145-y · Cited by 201
Molecular mechanisms involved in farnesol-induced apoptosis
Joo, J. H., & Jetten, A. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.05.015 · Cited by 197
Goveia, J., Stapor, P., & Carmeliet, P. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404156 · Cited by 200
“In addition, HMG-coA blockade also decreases geranyl-geranyl production, which reduces RhoA activity and restores a more beneficial eNOS/arginase balance (Goldstein & Brown, 1990; Liao & Laufs, 2005).”
Impact of HMG CoA reductase inhibition on small GTPases in the heart
Laufs, U. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00540-5 · Cited by 202
Fang, M., Kearns, B. G., Gedvilaite, A., Kagiwada, S., Kearns, M., Fung, M. K., & Bankaitis, V. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01036.x · Cited by 200
New aspects of sterol biosynthesis in growth and development of higher plants
Schaller, H. (2004) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2004.05.012 · Cited by 201
Pex19p, a Farnesylated Protein Essential for Peroxisome Biogenesis
Götte, K., Girzalsky, W., Linkert, M., Baumgart, E., Kammerer, S., Kunau, W.-H., & Erdmann, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.616 · Cited by 200
“It has been suggested that targeting to the appropriate location is realized by the specific adherence of defined prenylated proteins to organelle-specific membrane receptors (31, 33, 66).”
BackgroundSato, R., Yang, J., Wang, X., Evans, M. J., Ho, Y. K., Goldstein, J. L., & Brown, M. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32550-4 · Cited by 197
Self-citationDifferential Regulation of Rat and Human CYP7A1 by the Nuclear Oxysterol Receptor Liver X Receptor-α
Goodwin, B., Watson, M. A., Kim, H., Miao, J., Kemper, J. K., & Kliewer, S. A. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0246 · Cited by 198
Lorbek, G., Lewinska, M., & Rozman, D. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08432.x · Cited by 196
Intracellular cholesterol transport.
Liscum, L., & Dahl, N. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40539-5 · Cited by 197
PANNU, R., & SINGH, I. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.04.010 · Cited by 195
Differential Regulation of Endoplasmic Reticulum Structure through VAP-Nir Protein Interaction
Amarilio, R., Ramachandran, S., Sabanay, H., & Lev, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409566200 · Cited by 196
Kevei, Z., Lougnon, G., Mergaert, P., Horváth, G. V., Kereszt, A., Jayaraman, D., Zaman, N., Marcel, F., Regulski, K., Kiss, G. B., et al. (2007) · The Plant Cell · doi:10.1105/tpc.107.053975 · Cited by 200
“As only the active NORK kinase showed interaction with HMGR1 in the Y2H assay, kinase activity might be required for autophosphorylation of NORK or phosphorylation of HMGR1, which may lead to inactivation of the enzyme (Goldstein and Brown, 1990).”
BackgroundLith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice.
Khanuja, B., Cheah, Y. C., Hunt, M., Nishina, P. M., Wang, D. Q., Chen, H. W., Billheimer, J. T., Carey, M. C., & Paigen, B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7729 · Cited by 196
Ohgami, N., Ko, D. C., Thomas, M., Scott, M. P., Chang, C. C. Y., & Chang, T.-Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405255101 · Cited by 200
Näär, A. M., Beaurang, P. A., Robinson, K. M., Oliner, J. D., Avizonis, D., Scheek, S., Zwicker, J., Kadonaga, J. T., & Tjian, R. (1998) · Genes & Development · doi:10.1101/gad.12.19.3020 · Cited by 194
Is methyl farnesoate a crustacean hormone?
Nagaraju, G. P. C. (2007) · Aquaculture · doi:10.1016/j.aquaculture.2007.05.014 · Cited by 192
Cerivastatin Improves Survival of Mice with Lipopolysaccharide-Induced Sepsis
Ando, H., Takamura, T., Ota, T., Nagai, Y., & Kobayashi, K.-I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39169-4 · Cited by 194
Uptake of Dietary Coenzyme Q Supplement is Limited in Rats
Zhang, Y., Åberg, F., Appelkvist, E.-L., Dallner, G., & Ernster, L. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.3.446 · Cited by 191
Effects of Fluvastatin on Leukocyte–Endothelial Cell Adhesion in Hypercholesterolemic Rats
Kimura, M., Kurose, I., Russell, J., & Granger, D. N. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.8.1521 · Cited by 193
Ohnaka, K., Shimoda, S., Nawata, H., Shimokawa, H., Kaibuchi, K., Iwamoto, Y., & Takayanagi, R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5597 · Cited by 193
In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
Jiang, P., Mukthavaram, R., Chao, Y., Nomura, N., Bharati, I. S., Fogal, V, Pastorino, S., Teng, D., Cong, X., Pingle, S. C., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.431 · Cited by 194
“This is the rate-limiting step in cholesterol biosynthesis (Goldstein and Brown, 1990).”
Background
Metadata
- Authors
- Goldstein, J. L., & Brown, M. S.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Venue
- Nature
- Published
- 1990-02
- Volume
- 343
- Issue
- 6257
- Pages
- 425-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2071124826
- Cited by
- 5,394
- References
- 84
- Citations by year
- 2026: 78 · 2025: 101 · 2024: 104 · 2023: 123 · 2022: 143 · 2021: 145 · 2020: 152 · 2019: 147 · 2018: 138 · 2017: 126 · 2016: 146 · 2015: 189 · 2014: 201 · 2013: 180 · 2012: 161
- FWCI
- 33.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Plant biochemistry and biosynthesis
- Keywords
- mevalonate pathway, terpenoids, feedback regulation, LDL receptor, cholesterol biosynthesis, growth regulation, cancer therapy, heart disease
- MeSH terms
- Animals, Cell Division, Cholesterol, Farnesol, Gene Expression Regulation, Humans, Hydroxymethylglutaryl CoA Reductases, Hydroxymethylglutaryl-CoA Synthase, Mevalonic Acid, Receptors, LDL, Sterols, Transcription, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.